Home > Insider Trading > Filing (0000950170-25-025011)

Filing Details

Accession Number:: 0000950170-25-025011
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-02-21 17:48:02
Reporting Period:: 2025-02-19

Filing Date:: 2025-02-21
Accepted Time:: 2025-02-21 17:48:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1707502	Solid Biosciences Inc.	SLDB	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1702921	Bcip Life Sciences Associates, Lp	200 Clarendon Street Boston MA 02116	No	No	No	No
1703030	Bain Capital Life Sciences Partners, Lp	200 Clarendon Street Boston MA 02116	No	No	No	No
1703031	Bain Capital Life Sciences Investors, Llc	200 Clarendon Street Boston MA 02116	No	No	No	No
1728056	Bcls Sb Investco, Lp	200 Clarendon Street Boston MA 02116	No	No	No	No
1773187	Bain Capital Life Sciences Fund Ii, L.p.	200 Clarendon Street Boston MA 02116	No	No	No	No
1796155	Bain Capital Life Sciences Investors Ii, Llc	200 Clarendon Street Boston MA 02116	No	No	No	No
1814474	Bcls Ii Equity Opportunities, Lp	200 Clarendon Street Boston MA 02116	No	No	No	No
1818893	Bcls Ii Investco, Lp	200 Clarendon Street Boston MA 02116	No	No	No	No
1819101	Bcls Ii Investco (Gp), Llc	200 Clarendon Street Boston MA 02116	No	No	No	No
2008174	Bcls Ii Equity Opportunities Gp, Llc	200 Clarendon Street Boston MA 02116	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-02-19	1,000,000	$4.03	5,034,582	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Pre-Funded Warrant (right to buy)	Acquisiton	2025-02-19	6,444,170	$4.03	6,444,170	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
6,444,170	2025-02-19		No	4	P	Indirect

Footnotes

On February 19, 2025, BCLS II Investco, LP ("BCLS II Investco") purchased 1,000,000 shares of the Issuer's common stock and a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock at a purchase price of $4.03 and $4.029, respectively, in an underwritten public offering (the "February 2025 Underwritten Offering").
The pre-funded warrant cannot be exercised if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then outstanding immediately following such exercise.
The pre-funded warrant does not expire.
Represents 528,660 shares of the Issuer's common stock held directly by BCLS SB Investco, LP ("BCLS SB"), 267,257 shares of the Issuer's common stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), 3,301,955 shares of the Issuer's common stock held directly by BCLS II Investco, 904,160 shares of the Issuer's common stock held directly by BCLS II Equity Opportunities, LP ("BCLS II Equity") and 32,550 shares of the Issuer's common stock held directly by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II Investco, BCLS SB, BCLS Fund II and BCLS II Equity, the "Bain Capital Life Sciences Entities"), after giving effect to the closing of the February 2025 Underwritten Offering.
Represents a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock held directly by BCLS II Investco, after giving effect to the closing of the February 2025 Underwritten Offering.
Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS SB. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS SB. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS Fund II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
BCLS II Equity Opportunities GP, LLC ("BCLS II Equity GP"), whose manager is BCLS Fund II, is the general partner of BCLS II Equity. As a result, each of BCLSI II, BCLS Fund II and BCLS II Equity GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Equity. Each of BCLSI II, BCLS Fund II and BCLS II Equity GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Boylston Coinvestors, LLC is the general partner of BCIPLS.
Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the general partner of BCLSP, (ii) is the manager of BCLSI II and (iii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.